RecruitingNCT07680140
Using biomarkers to guide iTBS or ketamine for treatment-resistant depression
About this title
Read the official source — NCT07680140Medication studyAges 18–70United States
Understand this study
Who could participate?
Listed age limits: 18 years to 70 years.
- Listed locations
- New YorkSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: August 10, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 27
- Sponsor
- Weill Medical College of Cornell University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- DEVICE, Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT07680140
- Official title
Show the full official title
Biomarker-Guided Antidepressant Selection for Treatment-Resistant Depression
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
New York
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Weill Medical College of Cornell University, a university.
Does this study involve medication?
Yes. The study involves medication, including ketamine.
Who can participate?
Listed age limits: 18 years to 70 years.
Is this study still recruiting?
The registry lists this study as recruiting.
